Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$670 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
10.8
Industry P/E
--
EV/EBITDA
-0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.7
Face value
--
Shares outstanding
9,787,161
CFO
CA$-28.26 Mln
EBITDA
CA$-31.37 Mln
Net Profit
CA$-31.64 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
| -10.5 | -16.7 | -10.5 | 93.5 | 216.6 | 21.2 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
| 116.7 | -61.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 |
|
BSE Sensex
| 9.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
|
69.9 | 669.9 | 0.0 | -19.8 | -- | -28.1 | -- | 10.8 |
| 5.2 | 413.1 | 0.0 | -131.6 | -- | -61.8 | -- | 1.0 | |
| 1.0 | 86.6 | 0.0 | -35.3 | -- | -1067.3 | -- | 1,236.3 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for... epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York. Address: 19 Vestry Street, New York, NY, United States, 10013 Read more
Co-Founder, CEO, President & Director
Mr. Ian McDonald
Co-Founder, CEO, President & Director
Mr. Ian McDonald
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bright Minds Biosciences Inc (DRUG) is $70.37 (NASDAQ) as of 02-Apr-2026 12:35 EDT. Bright Minds Biosciences Inc (DRUG) has given a return of 216.64% in the last 3 years.
Since, TTM earnings of Bright Minds Biosciences Inc (DRUG) is negative, P/E ratio is not available.
The P/B ratio of Bright Minds Biosciences Inc (DRUG) is 10.77 times as on 31-Mar-2026, a 251 premium to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-34.72
|
5.18
|
|
2024
|
-1.67
|
0.85
|
|
2023
|
-0.87
|
0.97
|
|
2022
|
-0.16
|
0.23
|
|
2021
|
--
|
--
|
The 52-week high and low of Bright Minds Biosciences Inc (DRUG) are Rs 123.75 and Rs 23.18 as of 02-Apr-2026.
Bright Minds Biosciences Inc (DRUG) has a market capitalisation of $ 670 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bright Minds Biosciences Inc (DRUG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.35
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.